10-Q: Utah Medical Products Reports Lower Sales and Earnings in Second Quarter 2024

Utah Medical Products experienced a decrease in sales and earnings in the second quarter of 2024, primarily due to reduced demand from a major OEM customer and lower sales in key product categories.

Summary

• Utah Medical Products reported a 19.2% decrease in net sales for the second quarter of 2024, totaling $10.4 million, compared to $12.866 million in the same period of 2023.
• The company's gross profit also decreased by 19.2%, aligning with the sales decline, while maintaining a gross profit margin of 60.1%.
• Operating income for the quarter fell by 22.3% to $3.438 million, and net income decreased by 17.8% to $3.453 million.
• Earnings per diluted share were $0.98, a 15.3% decrease from $1.15 in the second quarter of 2023.
• For the first half of 2024, net sales were down 14.4% to $21.74 million, and net income decreased by 11.9% to $7.409 million.
• The company's cash and investments decreased to $89.219 million as of June 30, 2024, from $92.868 million at the end of 2023.
• The decline in sales was primarily attributed to lower sales to a major biopharmaceutical OEM customer, reduced shipments to a Chinese distributor, and decreased sales of the Filshie Clip System.
• UTMD now projects 2024 sales to be 20-22% lower than in 2023 due to lack of orders from its previous largest OEM customer and ongoing weakness in Filshie device sales.

Sentiment

Score: 4

Explanation: The document presents a negative outlook due to significant declines in sales and earnings, coupled with a reduced full-year sales projection. While the company maintains a strong balance sheet and continues share repurchases, the overall tone is pessimistic due to the poor financial results and future outlook.

Positives

• The company maintained a consistent gross profit margin of 60.1% in the second quarter of 2024 despite lower sales.
• UTMD achieved similar profit margins in all income categories compared to the prior year's same periods.
• The company's balance sheet remains strong with no debt.
• UTMD continues to repurchase shares, indicating confidence in its long-term value.
• The company's current ratio remains strong at 26.0 as of June 30, 2024.
• The company's average age of trade receivables was 32 days, indicating excellent collection experience.
• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.

Negatives

• Net sales decreased by 19.2% in the second quarter of 2024 compared to the same period in 2023.
• Operating income decreased by 22.3% in the second quarter of 2024.
• Net income decreased by 17.8% in the second quarter of 2024.
• Earnings per diluted share decreased by 15.3% in the second quarter of 2024.
• The company experienced a significant decline in sales to its previously largest OEM customer.
• Sales of the Filshie Clip System also declined in the second quarter of 2024.
• The company's cash and investments decreased by $3.65 million during the first half of 2024.
• UTMD now projects 2024 sales to be 20-22% lower than in 2023.

Risks

• The company is facing a significant reduction in sales to its major OEM customer, which is expected to continue for the remainder of 2024.
• Ongoing weakness in Filshie device sales poses a risk to overall revenue.
• The company is involved in product liability litigation related to the Filshie Clip System, which could have an impact on financial results.
• Fluctuations in foreign currency exchange rates could impact the company's financial results.
• The company's average inventory turns declined to 1.8 in 2Q 2024, which is considered too low.

Future Outlook

UTMD expects 2024 sales to be 20-22% lower than in 2023 due to reduced demand from a major OEM customer and ongoing weakness in Filshie device sales. However, the company anticipates that operating profit for the year should be consistent with the beginning-of-year projection due to better-than-expected gross profit margin performance. EPS will benefit from share repurchases.

Management Comments

• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.
• The company intends to utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMDs existing infrastructure.
• If there are no better strategic uses for UTMDs cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

Industry Context

The medical device industry is facing challenges due to supply chain disruptions and changing customer demands. UTMD's results reflect these broader trends, particularly the impact of reduced orders from a major OEM customer. The company's focus on maintaining profitability despite lower sales is a common strategy in the current environment.

Comparison to Industry Standards

• While UTMD's gross profit margin of 60.1% is strong, the significant decline in sales and earnings is concerning when compared to industry leaders such as Medtronic and Johnson & Johnson, which have shown more resilience in their recent quarterly results.
• Medtronic, for example, reported a 4.8% increase in revenue in their most recent quarter, while Johnson & Johnson's medical device segment saw a 6.3% increase in sales, indicating a stronger performance than UTMD.
• UTMD's reliance on a single major OEM customer also highlights a risk not typically seen in larger, more diversified medical device companies.
• The company's share repurchase program is a positive sign, but it may not be enough to offset the negative impact of lower sales and earnings compared to industry benchmarks.

Legal Proceedings

• UTMD is involved in product liability lawsuits related to the Filshie Clip System, which are still in the discovery phase.

Stakeholder Impact

• Shareholders will be impacted by the lower earnings and reduced sales projections.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Customers may experience changes in product availability and pricing.
• Suppliers may see a reduction in orders due to lower sales.

Next Steps

• The company plans to continue to invest in ways that will enhance future profitability.
• UTMD will make additional investments in new technology and/or processes.
• The company will remain vigilant for affordable accretive acquisition opportunities.
• UTMD will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

Key Dates

Keywords

medical devices, sales, earnings, profitability, OEM, Filshie Clip System, biopharmaceutical, blood pressure monitoring, stock repurchase, financial results